Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376752 | 1.00 | MMP2 (0.37) | MMP2ANPEPPDK1 | |
| SCHEMBL4303400 | 0.85 | ATM (0.39) | PDK1 | |
| SCHEMBL376313 | 0.85 | ATM (0.39) | PDK1 | |
| SCHEMBL22557040 | 0.83 | MMP2 (0.42) | MMP2ANPEP | |
| SCHEMBL3955349 | 0.83 | MMP2 (0.42) | MMP2ANPEP | |
| SCHEMBL376497 | 0.83 | MMP2 (0.42) | MMP2ANPEP | |
| SCHEMBL22696578 | 0.82 | MMP2 (0.34) | MMP2ANPEPPDK1 | |
| SCHEMBL10239523 | 0.81 | NR1H2 (0.38) | MMP2ANPEP | |
| SCHEMBL13662051 | 0.81 | NR1H2 (0.38) | MMP2ANPEP | |
| SCHEMBL3945701 | 0.77 | MMP2 (0.35) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | MMP2 57/4885ANPEP 129/4885PDK1 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.